Lineage Cell Therapeutics (LCTX) Receivables (2011 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Receivables came in at $1.4 million in Q1 2026, up 553.05% year-on-year from $213000.0 in Q1 2025, and down 10.95% quarter-over-quarter from $1.6 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Receivables (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Receivables history runs 16 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- On a quarterly basis, Receivables rose 553.05% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 553.05% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 144.83% from the prior year.
- Receivables retreated to $1.4 million in Q1 2026 per LCTX's latest filing, from $1.6 million in the prior quarter.
- Across five years, Receivables topped out at $1.6 million in Q4 2025 and bottomed at $77000.0 in Q1 2024.
- The 5-year median for Receivables is $432000.0 (2023), against an average of $583823.5.
- Across the five-year window, Receivables sank 98.28% in 2022 and soared 553.05% in 2026, its largest moves.
- Year by year, Receivables stood at $881000.0 in 2022, then fell by 15.44% to $745000.0 in 2023, then decreased by 14.36% to $638000.0 in 2024, then surged by 144.83% to $1.6 million in 2025, then fell by 10.95% to $1.4 million in 2026.
- Per Business Quant, the three latest LCTX Receivables figures stand at $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $676000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 676,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Mar 31, 2025 | 213,000.00 |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Dec 31, 2023 | 745,000.00 |
| Sep 30, 2023 | 432,000.00 |
| Jun 30, 2023 | 406,000.00 |
| Mar 31, 2023 | 173,000.00 |
| Dec 31, 2022 | 881,000.00 |
| Sep 30, 2022 | 980,000.00 |
| Jun 30, 2022 | 532,000.00 |
| Mar 31, 2022 | 323,000.00 |
| Dec 31, 2021 | 51.18 Mn |
| Sep 30, 2021 | 2.12 Mn |
| Jun 30, 2021 | 326,000.00 |